Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
Menu

Rutgers Cancer Institute of New Jersey Chair of Radiation Oncology and Associate Vice Chancellor of Cancer Programs Receives Prestigious National Award

Dr. Bruce G. Haffty Selected as 2020 Gold Medal Winner by American Society for Radiation Oncology
Wed, 05/27/2020 - 12:15
Dr. Haffty
Bruce G. Haffty, MD

New Brunswick, N.J., May 27, 2020 Bruce G. Haffty, MD,  associate vice chancellor for cancer programs and chair, radiation oncology at Rutgers Cancer Institute of New Jersey has been selected as the 2020 Gold Medal Award winner by the American Society for Radiation Oncology (ASTRO), the largest radiation oncology society in the world, in recognition of his significant accomplishments in the field. 

The ASTRO Gold Medal Award is given annually to individuals who have made outstanding lifetime contributions in the field of radiation oncology, including achievements in clinical patient care, research, teaching and service. With a special research interest in radiation therapy targeting breast cancer, Dr. Haffty works closely with colleagues across all disciplines and specialty centers at Rutgers Cancer Institute to conduct clinical and translational investigation and translate this work directly to patients.

“I am deeply humbled to be the recipient of this year’s Gold Medal Award from the American Society for Radiation Oncology. The institutional resources and environment initially at Yale and currently at Rutgers Cancer Institute has always provided me with unique opportunities to care for patients while advancing the field through clinical trials, research and education.  I share this award with the many students, residents and colleagues who have worked with me and I am most grateful for the support through the years of my wife Kathy and our family. It has been a privilege for me to be part of advancing this profession. I am grateful to ASTRO for this recognition and to my colleagues for holding me in such high regard,” notes Haffty, who is also Chair of Radiation Oncology at Rutgers Robert Wood Johnson Medical School and Rutgers New Jersey Medical School. 

Haffty joined Rutgers Cancer Institute in 2005, and has since overseen the growth of the Radiation Oncology Program to offer numerous sub-specialties and technologies not generally offered in a community setting, including proton therapy. Through decades of knowledge and experience, he also guides radiation oncology practices at University Hospital in Newark and throughout the Oncology Service Line at RWJBarnabas Health.

Haffty has served in many leadership roles related to research and education in radiation oncology. He has served as president of the American Board of Radiology, the major certifying organization for the practice of diagnostic radiology, radiation oncology, and medical physics. He also served as president and chairman of the board of ASTRO, has served as a past president of the American Radium Society and past chairman of the Residency Review Committee in Radiation Oncology. He currently serves as chairman of the board of the Radiological Society of North America Board (RSNA) and deputy editor of the Journal of Clinical Oncology. 

“Dr. Haffty has provided extraordinary leadership in building one of the premier radiation oncology departments in the country that offers numerous sub-specialties and sophisticated radiation therapies and modalities,” adds Steven K. Libutti, MD, FACS, director of Rutgers Cancer Institute and senior vice president, oncology services at RWJBarnabas Health. “I am honored to have Dr. Haffty as a member of our leadership team and am proud that he is the recipient of such a prestigious award.” 

 

About Rutgers Cancer Institute of New Jersey
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex robotic surgery.  Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities.

Along with world-class treatment, which is often fueled by on-site research conducted in Rutgers Cancer Institute laboratories, patients and their families also can seek cancer preventative services and education resources throughout the Rutgers Cancer Institute and RWJBarnabas Health footprint statewide. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving

 

###

For journalists – contact:
Krista Didzbalis 
Media Relations Assistant 
908-812-6114
krista.didzbalis@rutgers.edu 

 

For patient appointments/inquiries – contact:
844-CANCERNJ (844-226-2376)